Two Polymeric Complexes of Norfloxacin with Iron(II) and Their Magnetic Properties

Zhi-Rong Qu, [a] Hong Zhao, [a] Li-Xin Xing, [a] Xi-Sen Wang, [a] Zhen-Feng Chen, *[a] Zhi Yu, *[a] Ren-Gen Xiong, *[a] and Xiao-Zeng You [a]

Keywords: Nofloxacin / Iron / Coordination polymers / Magnetic properties / Hydrothermal synthesis

The reaction of H-Norf with $(NH_4)_2Fe(SO_4)_2 \cdot 6H_2O$ and $Fe(OH)_3$ (or Fe_2O_3) affords $Fe(H-Norf)_2(SO_4) \cdot 2H_2O$ (1) and $Fe(Norf)_2 \cdot 4H_2O$ (2), respectively, both of which have 2D polymeric structures. Their interesting magnetic properties are also reported. Crystal data for 1: monoclinic, $P2_1/c$, a = 23.166(1), b = 10.0492(4), c = 7.7264(3) Å, $\beta = 98.379(1)^\circ$, V = 2.166(1)

1779.50(13) ų, Z = 2; for **2**: monoclinic, $P2_1/c$, a = 5.8411(12), b = 21.685(4), c = 13.265(3) Å, $\beta = 99.20(3)^\circ$, V = 1658.6(6) ų, Z = 2.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)

Introduction

Norfloxacin (H-Norf, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid), an extremely potent antibacterial agent with a wide spectrum of activity, is increasingly used for the treatment of many infections. [1] The suggested modes of action of H-Norf are either an inhibition of metalloenzyme DNA-gyrase or an interaction with the DNA molecule via a metal complex intermediate, and it has been proposed that a copper or iron complex could be involved in these interactions with DNA. [2] Some quinolones inhibit the cytochrome P450 system, which also involves an iron(II) ion, and it has been reported that iron(II) sulfate impairs the absorption of quinolones due to the formation of chelates. [3] To date, no solid-state structure of an Fe-quinolone complex has been available to support this theory.

Iron deficiency anaemia is rather common but can be treated easily. By comparison, iron overload disease (IOLD) is relatively rare but can result in serious medical complications, including cirrhosis, primary liver cancer, diabetes, cardiomyopathy and arthritis. Since humans are unable to actively excrete iron, excess iron, once taken up, deposits in tissue in the form of solid FeOOH which then can lead to organ damage and ultimately death. More than 500000 patients world-wide who suffer IOLD (haematological defects such as β -thalassaemia major) can be treated by an iron chelator such as Desferal (siderophore desferrioxamine-B). [4] To date, no reaction product of a metal ion with quinolone derivatives is known to be a polymeric structure

Scheme 1

Results and Discussion

Crystals of dark brown 1 and brown-red 2 were harvested from the reaction of H-Norf with (NH₄)₂Fe(SO₄)₂·6H₂O and Fe(OH)₃, respectively (Scheme 1). The IR spectra of both 1 and 2 show two very strong peaks at 1621 and 1571cm⁻¹ for 1, and 1621 and 1462 cm⁻¹ for 2, indicating that the carboxylic acid groups of H-Norf are deprotonated (in comparison, those of free H-Norf are at 1710 and 1621 cm⁻¹). A strong peak at 1023 cm⁻¹ in the IR spectrum of 1 indicates that there is an uncoordinated SO₄²⁻. It is

Fax: (internat.) +86-25/331-7761 E-mail: xiongrg@netra.nju.edu.cn

both in weakly acidic and basic solutions, although a number of metal ion complexes have been reported. [5] To our surprise, the reaction of H-Norf with $(NH_4)_2$ -Fe(SO₄)₂·6H₂O and Fe(OH)₃ (or Fe₂O₃) affords Fe(H-Norf)(SO₄)·2H₂O (1) and Fe(Norf)₂·4H₂O (2) (Scheme 1), respectively, both of which have a 2D polymeric structure. Herein we report the synthesis of 1 and 2, their solid-state structures, and magnetic properties.

[[]a] Coordination Chemistry Institute, The State Key Laboratory of Coordination Chemistry, Nanjing University, 210093 Nanjing, P. R. China


SHORT COMMUNICATION

interesting to note that in weakly basic solution the N atom of the piperidyl ring can take part in the coordination to the metal ion, while in weakly acidic solution, this N atom is protonated and does not bind to the metal ion, as evidenced by the crystal-structure determinations below. Both 1 and 2 are insoluble in common solvents. The solubilities of 1 and 2 in water were estimated by ICP-AE (Inductively Coupled Plasma-Atomic Emission) to be 0.2 and 0.03 μ g/mL, respectively.

The X-ray crystal analysis of 1 revealed that the Fe^{II} ion is coordinated in a distorted octahedral geometry defined by six oxygen atoms from four different H-Norf ligands (Figure 1). Two H-Norfs afford one 4-oxo and one carboxyl oxygen to bind Fe^{II} to form two six-membered rings and one equatorial plane defined by O(1), O(2), O(1A) and O(2A), while the apical positions are occupied by two oxy-

gen atoms [(O3B) and O(3C)] from two different carboxylates of H-Norf. Thus, the carboxylate group of H-Norf in 1 clearly binds in a bidentate manner and links the Fe(H-Norf)₂ unit to form a 2D framework, as shown in Figure 1 (bottom). The framework core, composed of the 4-oxo and the 3-carboxyl oxygen atoms, is like a small 2D square grid. The N atom of the piperidyl ring in 1 loses its coordination capacity as a result of protonation. The crystal packing view also indicates that the anions (sulfate) and water are intercalated between two adjacent layers (see Supporting Information). There are also many hydrogen bonds, such as those between water and sulfate (2.547 Å), and water and the protonated N atom (2.711 Å), that hold two adjacent layers together.

The apical positions in 2 (Figure 2), unlike those in 1, are occupied by two N atoms [N(1) and N(2)] of piperidyl rings,







Figure 1. (top) An ORTEP symmetric unit diagram of $[Fe(H-Nor)_2]^2H_2O(SO_4)(1)$; H atoms and sulfate are omitted for clarity; selected bond lengths [A] and angles [°]: Fe(1)-O(1) 2.092(3), Fe(1)-O(2) 2.059(3), Fe(1)-O(3B) 2.251(3); O(1)-Fe(1)-O(2) 85.27(13), O(1)-Fe(1)-O(3B) 90.65(12), O(1)-Fe(1)-O(2A) 94.73(13), O(2)-Fe(1)-O(3B) 93.89(13), O(1)-Fe(1)-O(3C) 89.35(12); (bottom) an extended 2D network presentation of $[Fe(H-Nor)_2]^2H_2O(SO_4)(1)$ highlighting the Fe octahedron

resulting in the formation of a 2D square grid with a cavity dimension of 13.538×13.538 Å. [6] The coordination environment around Fe^{II} in 2 is also slightly distorted octahedral with an equatorial plane defined by O(2), O(3), O(2A) and O(3A) from two different Norfs. Unlike in 1, the carboxylate group of Norf in 2 acts as monodentate ligand, and one of the O atoms of the carboxylate group is uncoordinated. This mode of bonding is similar to that of Zn(Norf)2·4H2O.[5h]



(top) An ORTEP symmetric unit diagram of [Fe(Nor)₂]:4H₂O (2); H atoms are omitted for clarity; selected bond lengths [A] and angles [°]: $Fe(1)-O(2) \ 2.067(2)$, $Fe(1)-O(3) \ 2.105(2)$, $Fe(1)-N(1) \ 2.303(3)$; $O(2)-Fe(1)-O(3) \ 84.99(9)$, $O(2)-Fe(1)-O(3A) \ 95.01(9)$, $O(2)-Fe(1)-N(1B) \ 89.73(9)$, $O(2A)-Fe(1)-N(1B) \ 90.27(9)$, $O(3)-Fe(1)-N(1B) \ 92.90(10)$, O(3A)-Fe(1)-N(1B) 87.10(10); (bottom) an extended 2D molecular square presentation of [Fe(Nor)₂]·4H₂O (2) highlighting the

Studies of the magnetic susceptibility of 1 versus temperature (Figure 3) show strong antiferromagnetic coupling between 20 K and 300 K and a weak ferromagnetic phenomenon at lower temperatures (5-20 K). In contrast, 2 shows a weak ferromagnetic interaction throughout this whole temperature range. This is in good agreement with the shorter distance between the Fe ions in 1 than in 2. At room temperature the value of $\chi_{mol}T$ (≈ 3.5 cm³/mol K) for both compounds is rather close to the expected value for ferrous ion (S = 2) in a high-spin state; this was confirmed by Mössbauer spectra at room temperature. However, $\chi_{mol}T$ for 1 is discontinuous around 15 K, which is indicative of a magnetic phase-transition originating from a spin-canting phenomenon as a consequence of neighboring spin units of iron being aligned in a canted antiparallel manner.^[7] The magnetization of 1 at 5 K performed up to 50 kOe (Figure 4) shows that the field dependence of the magnetization departs from linearity. A hysteresis loop at very low magnetic field range (< 2000 Oe) was obtained. When the magnetic field was cycled, a remnant magnetization of about 0.3 µ_B and a coercive field of about 130 Oe were observed as a result of magnetic ordering at this temperature. This observation shows that 1 is a hard magnet material.




Figure 3. Temperature dependence of $\chi_{mol}T$ for 1 and 2




Figure 4. The magnetization of 1 in an applied field of -5 kOe to 5 kOe

In conclusion, the reaction products of H-Norf with iron(II) were found to be mainly dependent upon the pH of the solutions. In basic solution, the product is a 2D square network involving the coordination of the N atom of the piperidyl ring to iron(II), while in weakly acidic solution the product is also a 2D framework with a μ₃-carboxylate coordination mode.

Experimental Section

Compound 1: Samples of 1 mmol of (NH₄)₂Fe(SO₄)₂·6H₂O and 2 mmol of H-Norf were thoroughly mixed in a mortar with a pestle, and placed in thick-walled Pyrex tubes (ca. 20 cm long; pH ≈ 5.8 in the solution). After addition of 0.5 mL of EtOH and 1.5 mL of H₂O, the tube was frozen with liquid N₂, evacuated under vacuum and sealed with a torch. The tube was heated at 105 °C for one day to give pale-yellow block crystals (0.454 g) in 55% yield based on H-Norf. C₃₂H₄₀F₂FeN₆O₁₂S (826.61): calcd. C 46.45, H 4.84,

SHORT COMMUNICATION

N 10.16; found C 46.58, H 4.90, N 10.28. The crystals showed only one phase. Solid reflectance UV/Vis (nm): 328.6, 271.7. IR (KBr): $\tilde{v}=3402(m),\ 1621(s),\ 1462(vs),\ 1371(w),\ 1262(m),\ 1108(s),\ 1021(w),\ 925(w),\ 804(w),\ 791(w),\ 745(w)$ and 620(w) cm $^{-1}$.

Compound 2: The procedures are similar to those of **1** and Fe(OH)₃ was used as starting material (pH \approx 8.2). The brown-red rod crystals (0.497 g; one phase) were harvested in 65% yield based on H-Norf. $C_{32}H_{42}F_2FeN_6O_{10}$ (764.57): calcd. C 50.22, H 5.49, N 10.99; found C 50.30, H 5.55, N 11.12. IR (KBr): $\tilde{v} = 3400$ (m), 1620(vs), 1578(m), 1482(s), 1380(m), 1340(m), 1261(s), 182(w),1118 (w), 1000(w), 928(m), 884(w),811(w), 790(w), 740(w) and 628(w) cm⁻¹.

Crystal Data for 1: $C_{32}H_{40}F_2FeN_6O_{12}S$, $M_r=826.61$, monoclinic, $P2_1/c$, a=23.166(1), b=10.0492(4), c=7.7264(3) Å, $\beta=98.379(1)^\circ$, V=1779.50(13) Å, Z=2, $\rho_{calcd.}=1.543~{\rm grcm}^{-3}$, T=293(2) K, $\mu=0.565~{\rm mm}^{-1}$, $R_1=0.0633$, wR2=0.1589 for 1975 observed reflections from 3121 independent reflections, GOF = 1.032.

Crystal Data for 2: $C_{32}H_{42}F_2FeN_6O_{10}$, $M_r=764.57$, monoclinic, $P2_1/c$, a=5.8411(12), b=21.685(4), c=13.265(3) Å, $\beta=99.20(3)^\circ$, V=1658.6(6) Å 3 , Z=2, $\rho_{calcd.}=1.531$ g cm $^{-3}$, T=293(2) K, $\mu=0.534$ mm $^{-1}$, $R_1=0.0496$, $wR_2=0.1456$ for 2033 observed reflections from 2869 independent reflections, GOF = 1.189.

The structures were solved by direct methods using the program SHELXTL. All the non-hydrogen atoms were located from the trial structure and then refined anisotropically with SHELXTL using a full-matrix least-squares procedure. The hydrogen atom positions were fixed geometrically at calculated distances and allowed to ride on the parent carbon atoms. The final difference Fourier map was found to be featureless.

CCDC-140822 (1) and -169760 (2) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; Fax: (internat.) +44-1223/336-033; E-mail: deposit@ccdc.cam.ac.uk].

Acknowledgments

This work was funded by The Major State Basic Research Development Program (Grant No. G2000077500) and the National Natural Science Foundation of China. R.-G. X. thanks Prof. Dr. H.-K. Fun for the X-ray crystal structure determination of compound 1.

- [2] [2a] L. L. Shen, J. Baranowski, A. G. Pernet, *Biochemistry* 1989, 28, 3879.
 [2b] A. J. Maxwell, *Antimicrob. Chemoth.* 1992, 30, 409.
 [2c] C. J. R. Willmott, S. E. Chritchlow, I. C. Eperson, A. J. Maxwell, *Mol. Biol.* 1994, 242, 351.
 [2d] P. A. Permana, R. M. Snapka, L. L. Shen, D. T. W. Chu, J. J. Clement, J. J. Platter, *Biochemistry* 1994, 33, 11333.
 [2e] H. Yu, L. H. Hurley, S. M. Kerwin, *J. Am. Chem. Soc.* 1996, 118, 7040.
 [2f] H. T. Yu, Y. Kwok, L. H. Hurley, S. M. Kerwin, *Biochemistry* 2000, 39, 10236
- [3] [3a] J. R. B. J. Brouwers, *Drug Safety* 1992, 7, 268. [3b] I. Turel, I. Leban, G. Klintschar, N. Bukovec, S. Zalar, *J. Inorg. Biochem.* 1997, 63, 77. [3c] F. Gao, P. Yang, J. Xie, H. Wang, *J. Inorg. Biochem.* 1995, 60, 61.
- [4] [4a] U. Heinz, K. Hegetschweiler, P. Acklin, B. Faller, R. Lattmann, H. P. Schnebli, Angew. Chem. Int. Ed. 1999, 38, 2568. [4b] R. C. Hider, A. D. Hall, Prog. Med. Chem. 1991, 28, 40. [4c] J.-B. Galey, O. Destree, J. Dumates, S. Genard, P. Tachon, J. Med. Chem. 2000, 43, 1418. [4d] B. Crichton, M. Green, Curr. Med. Res. Opin. 2002, 18, 92. [4e] G. J. Kontoghiorghes, M. B. Agarwal, P. Tondury, J. J. M. Marx, Lancet 2001, 357, 882.
- [5] [5a] C. Chulvi, M. C. Munoz, L. Perello, R. Ortiz, M. I. Arriortua, J. Via, K. Urtiaga, J. M. Amigo, L. E. Ochando, J. Inorg. Biochem. 1991, 42, 133. [5b] G. Mendoza-Diuz, L. M. R. Martinez-Aguilera, R. M. Esparza, K. H. Panell, F. C. Lee, J. Inorg. Biochem. 1993, 50, 65. [5c] M. Ruiz, R. Ortiz, A. Castinerias, M. Quiros, Inorg. Chim. Acta 1993, 211, 133. [5d] I. Turel, I. Leban, N. Bukovec, J. Inorg. Biochem. 1994, 56, 273. [5e] S, C. Wallis, L. R. Gahan, B. G. Charles, T. W. Hambley, P. A. Duckworth, J. Inorg. Biochem. 1996, 62, 1. [5f] I. Turel, K. Gruber, I. Leban, N. Bukovec, J. Inorg. Biochem. 1996, 61, 197. [5g] Z.-F. Chen, R.-G. Xiong, J.-L. Zuo, Z. Guo, X.-Z. You, H.-K. Fun, J. Chem. Soc., Dalton Trans. 2000, 4013. [5h] Z.-F. Chen, R.-G. Xiong, J. Zhang, X.-T. Chen, Z.-L. Xue, X.-Z. You, Inorg. Chem. 2001, 40, 4075. [5i] Z.-F. Chen, B.-Q. Li, Y.-L. Yuan, R.-G. Xiong, X.-Z. You, X.-L. Feng, Inorg. Chem. Commun. 2001, 4, 346.
- [6] [6a] M. Aoyagi, K. Biradha, M. Fujita, J. Am. Chem. Soc. 1999, 121, 7457.
 [6b] T. Shimizu, M. Kogiso, M. Masuda, Nature 1996, 383, 487.
 [6c] Z. Guo, P. J. Sadler, Angew. Chem. Int. Ed. 1999, 38, 1512.
 [6d] Z. Guo, P. J. Sadler, Adv. Inorg. Chem. 1999, 49, 183.
- [7] [7a] C.-M. Liu, Z. Yu, R.-G. Xiong, X.-Z. You, *Inorg. Chem. Commun.* 1999, 1, 31. [7b] M. Martinez-Lorente, J. P. Tuchagues, V. Petrouleas, J. M. Savariault, R. Poinsot, M. Drillon, *Inorg. Chem.* 1991, 30, 3587. [7c] H. Oshio, N. Hoshino, T. Ito, *J. Am. Chem. Soc.* 2000, 122, 12602. [7d] K. L. Taft, A. Caneschi, L. E. Pence, C. D. Delfs, G. C. Papaefthymiou, S. J. Lippard, *J. Am. Chem. Soc.* 1993, 115, 11753. [7e] A. L. Barra, A. Caneschi, A. Cornia, F. Fabrizi de Biani, D. Gatteschi, C. Sangregorio, R. Sessoli, L. Sorace, *J. Am. Chem. Soc.* 1999, 121, 5302. [7f] S. M. J. Autin, M. W. Wemple, L.-C. Brunel, M. B. Maple, G. Christou, D. N. Hendrickson, *J. Am. Chem. Soc.* 1996, 118, 7746. [7g] J. L. Manson, Q.-Z. Huang, J. W. Lynn, H.-J. Koo, M.-H. Whangbo, R. Bateman, T. Otsuka, N. Wada, D. N. Argyriou, J. S. Miller, *J. Am. Chem. Soc.* 2001, 123, 162. Received April 28, 2003

^{[1] [1}a] L. L. Shen, A. G. Pernet, Proc. Natl. Acad. Sci. USA 1985, 82, 307. [1b] G. C. Grumplin, J. M. Midgley, J. T. Smith, Top. Antibiot. Chem. 1980, 8 9. [1c] Quinolone Antimicrobial Agents, 2nd ed. (Eds.: D. C. Hooper, J. S. Wolfson), American Society of Microbiology, Washington DC, 1993. [1d]G. S. Son, J.-A. Yeo, M.-S. Kim, S. K. Kim, A. Holmen, B. Akerman, B. Norden, J. Am. Chem. Soc. 1998, 120, 6451.